HIV-1 Mutations and Antiretroviral Therapy
Author Information
Author(s): Shiri Tinevimbo, Welte Alex
Primary Institution: University of the Witwatersrand
Hypothesis
Does transient antiretroviral therapy increase the risk of rare HIV-1 mutations?
Conclusion
Transient increases in common HIV-1 mutants are linked to faster emergence of rarer mutations.
Supporting Evidence
- Transient therapy significantly increases the hazards of rare mutations.
- The probability of observing a rare mutation is negligible without therapy.
- Transient therapy dramatically increases the probability of observing a rare mutation.
Takeaway
When people take certain HIV medicines, it can make some germs stronger and help them change into even trickier germs.
Methodology
A hybrid deterministic-stochastic model was developed to analyze the dynamics of healthy and infected T cell populations under different treatment scenarios.
Potential Biases
Potential biases in the model due to assumptions about mutation rates and treatment effects.
Limitations
The model may not capture all complexities of HIV dynamics and the persistence of rare mutants is not fully understood.
Participant Demographics
Women receiving single dose nevirapine for PMTCT.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website